Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
In U2OS cells expressing FFA4, AH-7614 (Compound 39) (0.063-1 μM) inhibits the intracellular Ca2+ response brought on by linoleic acid and FFAR4 agonist [1]. In NCI-H716 cells, the increasing impact of GSK137647A on glucose-stimulated insulin production was eliminated by AH-7614 (100 μM) [1]. TUG-891-mediated internalization of FFA4 from the cell surface is blocked by AH-7614 (0.001-10 μM; 15 minutes) (pIC50=7.70) [2]. AH-7614 (10 μM; 30 minutes) inhibits intracellular myo-inositol monophosphate and FFA4 phosphorylation increases brought on by agonists [2].
|
---|---|
ln Vivo |
In mice, AH7614 (50 μg administered intraperitoneally every 4 μd for 20 days) can inhibit the formation of tumors [3]. ? When paired with epirubicin, AH7614 (50 μg; intratumoral injection given one day prior to the latter) can increase the susceptibility of cancer cells to chemotherapy by blocking GPR120 signaling and preventing tumor growth [3].
|
References |
|
Molecular Formula |
C20H17NO3S
|
---|---|
Molecular Weight |
351.42
|
Exact Mass |
351.093
|
Elemental Analysis |
C, 68.36; H, 4.88; N, 3.99; O, 13.66; S, 9.12
|
CAS # |
6326-06-3
|
PubChem CID |
233085
|
Appearance |
White to off-white solid powder
|
Density |
1.37g/cm3
|
Boiling Point |
505.9ºC at 760mmHg
|
Flash Point |
259.8ºC
|
Index of Refraction |
1.685
|
LogP |
5.64
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
4
|
Rotatable Bond Count |
3
|
Heavy Atom Count |
25
|
Complexity |
528
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
OZCQEUZTOAAWDK-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C20H17NO3S/c1-14-10-12-15(13-11-14)25(22,23)21-20-16-6-2-4-8-18(16)24-19-9-5-3-7-17(19)20/h2-13,20-21H,1H3
|
Chemical Name |
4-methyl-N-(9H-xanthen-9-yl)benzenesulfonamide
|
Synonyms |
AH-7614 AH7614 AH 7614
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~284.56 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8456 mL | 14.2280 mL | 28.4560 mL | |
5 mM | 0.5691 mL | 2.8456 mL | 5.6912 mL | |
10 mM | 0.2846 mL | 1.4228 mL | 2.8456 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.